What’s New in Idiopathic Pulmonary Fibrosis? Updated Diagnostic Guidelines and Fresh Evidence to Distinguish Among Treatment Options

Release Date: January 29, 2020
Last Reviewed: January 27, 2020
Expiration Date: January 29, 2021
Time to Complete Activity:  0.75 hour

Faculty
Lisa H. Lancaster, MD (Chair)

Associate Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Medical Director, Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Steering Committee  
Marilyn K. Glassberg, MD

Professor and Vice-Chair of Medicine
Chief of Pulmonary, Critical Care and Sleep 
Senior Director of Research Strategy and Growth
University of Arizona College of Medicine (Phoenix)
Phoenix, AZ
 
Steven D. Nathan, MD 
Professor of Medicine
Virginia Commonwealth University
Inova Fairfax Campus
Medical Director, Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA 

Contributing Clinical Faculty 
Edwin F. Donnelly, MD, PhD
Associate Professor of Radiology and Radiological Sciences 
Vanderbilt University Medical Center
Associate Professor of Biomedical Engineering
Vanderbilt University 
Nashville, TN

Wendi R. Mason, MSN, RN, ACNP-BC
Assistant in Medicine, Nurse Practitioner
Director, ILD Research Unit 
Vanderbilt University Medical Center
Nashville, TN
 
Anne F. Turner, JD, BSN, RN
Clinical Coordinator, Interstitial Lung Disease Center
Vanderbilt Pulmonary Clinic 
Nashville, TN

Patient Faculty
Charles G. Capps, MS, PhD

Professor
College of Business
Lipscomb University
Nashville, TN
 
This activity is provided by Paradigm Medical Communications, LLC.  

Target Audience
This activity has been designed to address the educational needs of academic and community-based pulmonologists, radiologists, and pathologists. It may also benefit primary care physicians, nurse practitioners, PAs, pharmacists, nurses, residents, fellows, rheumatologists, and other healthcare professionals involved in the care of patients with idiopathic pulmonary fibrosis (IPF).

Statement of Need
The nonspecific symptoms of IPF challenge the healthcare team to differentially diagnose this deadly, progressive disease in a timely fashion. Because the treatments that are available to slow IPF progression, alleviate symptoms, and prolong life work best when initiated sooner rather than later, earlier diagnosis and immediate, evidence-based care are critical. This activity will review the latest guideline recommendations and data to support the multidisciplinary process needed to diagnose IPF earlier and more efficiently, and to treat it effectively. Experts will review new data that distinguish among both pharmaceutical and supportive measures, so clinicians can make informed treatment choices based on the best available evidence.

Learning Objectives
Upon proper completion of this activity, participants should be better able to:
•    Distinguish IPF from mimickers using guideline-recommended, multidisciplinary diagnostic evaluation approaches
•    Differentiate among pharmaceutical and supportive treatments for IPF, based on the latest recommendations and evidence
•    Formulate IPF treatment plans that accord with patient needs and goals

Chapters
IPF: A High-Impact Disease
Is This an ILD? If So, Is It IPF?
Considerations in Formulating an IPF Treatment Plan

Please note that patient details may represent a composite of information for educational purposes.

Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

PA Continuing Education
PAs may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.  Individuals are responsible for checking with the AANPCP for further guidelines.

This activity is supported by an educational grant from Genentech, Inc.    

Instructions for Participation 
To receive a CME certificate of participation, you should:
•    Follow instructions to register or log in with your professional information and complete the pre-activity assessment
•    View the online activity in its entirety
•    Complete and submit the online posttest and evaluation
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.

There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CME activity is designed using HTML5 video. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers:
For Desktops (Windows/Mac)
Microsoft Edge 40 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher

For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

Technical Support: If you have any technical problems or playback issues email us at contactus@paradigmmc.com.

Disclosures
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

Faculty 
Lisa H. Lancaster, MD (Chair)

Retained Consultant: Bellerophon Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc; Galapagos NV; Genentech, Inc
Grant/Research Support: Bellerophon Therapeutics; Biogen; Boehringer Ingelheim Pharmaceuticals, Inc; Celgene Corporation; Galapagos NV; Galecto Biotech; Novartis Pharmaceuticals Corporation
Speakers’ Bureau: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc
Salary (Spouse): Medtronic

Steering Committee
Marilyn K. Glassberg, MD 

Consultant/Independent Contractor: Actelion; Bellerophon Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Meyers Squibb; Genentech, Inc; RED-X
Grant/Research Support: Genentech, Inc
Honoraria: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc

Steven D. Nathan, MD 
Retained Consultant: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc
Speakers’ Bureau: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc

Contributing Clinical Faculty
Edwin F. Donnelly, MD, PhD 
Speakers’ Bureau: Genentech, Inc

Wendi R. Mason, MSN, RN, ACNP-BC 
No financial relationships to disclose

Anne F. Turner, JD, BSN, RN 
No financial relationships to disclose

Patient Faculty
Charles G. Capps, MS, PhD 

No financial relationships to disclose
 
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Independent peer reviewer has no financial relationships to disclose.
Independent fellow reviewer has no financial relationships to disclose.

Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity has been independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.

Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for use have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com. 

© 2020 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.